Background -The effect of adrenergic agonists in asthma depends on their net effect on microvascular leakage, mucosal oedema, vascular clearance of spasmogens, inhibition of cholinergic neurotransmission, and airway smooth muscle contractility. It has been postulated that adrenaline, by virtue of its alpha effects on the vasculature and cholinergic neurotransmission, may have additional useful properties in asthma compared with selective beta agonists such as salbutamol. Methods -The airway effects ofadrenaline (a non-selective adrenoreceptor agonist)
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were compared with the selective P2 agonist salbutamol. Their airway smooth muscle relaxant potencies and effect on histamine contraction in human bronchi in vitro were compared with their effects on airway calibre and histamine reactivity in asthmatic subjects in vivo. For the in vitro studies changes in tension were measured in response to these agents in thoracotomy specimens of human airways. In vivo the effects of adrenaline and salbutamol on airway calibre and histamine reactivity were measured in eight subjects with mild to moderate asthma in a randomised crossover study. Results -Salbutamol and adrenaline had approximately equivalent airway smooth muscle relaxant potencies in vitro and bronchodilator potency in vivo. However, their effects on histamine induced contraction in vitro were significantly different from their effects on histamine reactivity in vivo. Salbutamol was less potent in vitro producing a mean (SE) 2*4 (0.15) doubling dose increase in the histamine EC20 and adrenaline a 5 2 (0. 18) doubling dose increase (mean difference between salbutamol and adrenaline [2] [3] [4] [5] [6] [7] [8] doubling doses; 95% CI 1 1 to 4.5). Salbutamol had no effect on the maximal response to histamine whereas adrenaline reduced it by 54%. In contrast, salbutamol was more potent in vivo producing a mean (SE) increase in PD20 histamine of (0.5) doubling doses whereas adrenaline was without effect increasing PD20 by only 0*06 (0.47) doubling doses (mean difference between adrenaline and salbutamol 1-78, 95% CI 0-26 to 3-29 doubling doses). Conclusions -These findings suggest that the a adrenergic airway effects of nonselective adrenoreceptor agonists such as adrenaline offer no additional protection against histamine-induced bronchoconstriction in vivo than P2 selective drugs such as salbutamol, despite adrenaline providing greater protection against histamine-induced contraction in vitro. The differences between the effects of these agents in vitro and in vivo may be related to their opposing vascular effects in vivo. (Thorax 1994 Eight bronchial rings from each of the four subjects were studied (32 rings in total). A cumulative histamine concentration response study was performed on each ring, increasing amounts of histamine being added to each bath to produce cumulative bath concentrations over the range 10 --I 0-3mol/l in threefold increments. Each concentration was added at the plateau to the previous concentration. We have previously shown that the histamine concentration-response curve carried out in this way is very repeatable.'4 Rings were excluded from further study if the initial contraction to 10 mol/l histamine was less than 0 2 g. The tissues were then washed repeatedly over the next hour until tension had returned to baseline values. Adrenaline was then added to half of the rings to achieve a bath concentration of 10 -8mol/I and the maximum relaxant effect noted. This was followed by serial tenfold increases in cumulative bath concentrations up to 10-5mol/l, each additional dose being given after the response had plateaued. Similar relaxation concentration-response curves for salbutamol were measured in parallel rings. Allocation of paired rings to adrenaline or salbutamol was random. The total duration of the concentration-response was similar for salbutamol and adrenaline. Immediately after the maximum relaxant effect of the last dose was established (10-5mol/l for both agents, a further cumulative histamine concentrationresponse study was performed in an identical manner. Relaxation and contraction concentration-response curves were each performed over 10-15 minutes.
Drugs
Adrenaline and salbutamol were obtained from Sigma Chemicals, Poole, UK. Histamine acid phosphate was obtained from BDH Chemicals, Poole, UK. All drugs were dissolved in water.
Analysis
All contractile responses were expressed as a percentage of the initial maximal response to 10-3mol/l histamine. The contractile effect of histamine was expressed as the concentration of drug producing either 20% and 50% of the initial maximal contraction (EC20 and ECso) and the mean values before and after the drug were compared using analysis of variance. In addition, the maximum contractile responses to 10-'3mol/l histamine after drugs were compared by analysis of variance. The relaxant effects of salbutamol and adrenaline on inherent tone were compared at EC20 and EC50 values which were the concentrations of drug which produced 20% and 50% of maximal relaxation. The change in tension below baseline induced by adrenaline or salbutamol in these studies was expressed as a % ofthe tension generated by the initial histamine contraction. This standardised the response for the amount of airway smooth muscle present in each bronchial ring. The results in this study were identical whether they were expressed in this manner or in absolute terms in grams of tension. A p value of <0 05 was regarded as being statistically significant.
IN VIVO STUDY Subjects
Eight men aged between 24 and 51 years with mild to moderate asthma and requiring inhaled therapy alone were studied. They were otherwise healthy and had not had a respiratory tract infection within four weeks of the first study visit. All subjects had a resting forced expiratory volume in one second (FEVI) >60% of their predicted value and had previously demonstrated an improvement in FEV, of greater than 15% after 200 Rtg inhaled salbutamol. They also had a provocative dose of histamine causing a 20% fall in FEV, (PD20 FEV, hist) of <4 jimol. All were taking inhaled ,B agonists either alone or with inhaled corticosteroids. Medications were continued unchanged throughout the study although P agonists were withheld six hours before each study visit. Subjects gave written consent to participation in the study which was approved by the Nottingham City Hospital ethics committee. Measurements FEV, was measured using a dry bellows spirometer (Vitalograph, Buckingham, UK) as the higher of the two successive readings within 100 ml. Histamine challenge was performed by the method of Yan et al'5 using DeVilbiss No 40 hand-held nebulisers (DeVilbiss Co, Pennsylvania, USA). After baseline FEV, had been measured, subjects inhaled 0 9% saline followed by doubling doses (0-03-8 tmol) of histamine with measurement of FEV, 60 seconds after each inhalation. The challenge was discontinued when the FEV, had fallen by 20% or more from post saline values. PD20 FEV, was estimated by linear interpolation on a log dose-response plot.
Protocol
The study had a randomised, double blind, crossover design. Subjects attended the laboratory on two non-consecutive days of the same week at the same time of day. After resting in the sitting position for 15 minutes, baseline measurements of heart rate, blood pressure, and FEV, were made, and a histamine challenge test performed. One hour later, provided the FEV, had returned to within 95% of the baseline level, subjects were asked to inhale four sequential doses (0 4, 4, 40, and 400 tg) of either salbutamol or adrenaline solutions at 10 minute intervals in a cumulative manner via an Inspiron Minineb nebuliser (Bard, Sun- When the bronchodilator effect of salbutamol and adrenaline were compared at each dose no significant difference was found.
Bronchial reactivity Salbutamol produced a rise in mean (SE) PD20
histamine from 036 (0-13) jmolto 1-29 (0-17) gimol -that is, 1-84 doubling doses -whereas adrenaline caused a rise from 0 38 (0 10) ,umol to 0-39 (0-15) gmol -that is, 0-06 doubling doses ( fig 4) . The difference in change in PD20 between salbutamol and adrenaline was 1 78 (95% CI 0-26 to 3 29) doubling doses, p <0 05. There were no significant changes in pulse rate or blood pressure during the study period.
IceXs DeLWeen U1n preZUrUoncoUUliaLUl-va-Discussion rthe tissue groups treated with the two We found that the bronchodilator potencies of . Both drugs caused an increase in EC20 adrenaline and salbutamol were equivalent in tamine, and for adrenaline this was so asthmatic subjects in vivo. In previous studies Lerable that the EC50 could not be cal-in asthma inhaled salbutamol has been shown d for nine of the 13 preparations. The to produce a similar increase in FEV, to that (SE in log units) increase in EC20 after found in the present study when given in doses amol was 2-4 (0-15) This was the opposite of what we would have expected if the alpha effects of adrenaline are important. The change we saw with salbutamol is in agreement with several other studies in asthma.6"27-30 The only two previous studies to look at the effect of adrenaline on histamine responsiveness in vivo looked at physiological concentrations given intravenously,3"32 rather than pharmacological concentrations given by inhalation, and showed small reductions in histamine reactivity. In our present study local concentrations of adrenaline in the airway were likely to be much higher than in these studies due to the dosage and route used, and this might account for the difference by altering the ratio of a to 3 effects. The difference in protective effect of salbutamol and adrenaline on histamine responsiveness occurred despite the drugs producing equivalent bronchodilatation. The lack of correlation between bronchodilator properties of drugs and their effects on bronchoconstrictor challenges has previously been shown in studies comparing salbutamol and ipratropium.627
The difference between the relative effects of adrenaline and salbutamol on histamine responses in vivo was not due to differences in their ability to inhibit smooth muscle responses to histamine. Adrenaline had a profound effect on histamine-induced contractions in vitro whereas salbutamol had little effect at a concentration producing an identical degree of smooth muscle relaxation. The histamine response curve after adrenaline was much flatter than that after salbutamol. It is difficult to draw conclusions about the significance of this without dose ranging the effect of both drugs. Although the second histamine response curve performed in vitro was from a different baseline from the first, this is analogous to the situation in vivo and was the same for both drugs. This cannot, therefore, explain the difference between drugs. Interestingly, studies in guinea pig airways in vitro have also failed to show large shifts in histamine and muscarinic agonist induced concentration-response curves after another 32 selective drug, terbutaline.33 The authors inferred from their study that P2 agonists may be protecting against histamine-induced bronchoconstriction in vivo by an effect other than their smooth muscle effects. Our findings would support this. The greater effect of adrenaline on airway smooth muscle histamine responses in vitro is most likely to be due to the fact that it is a full agonist on P2 receptor whereas salbutamol is only a partial agonist.34 It is unlikely to represent an a effect as a adrenergic blockade has previously been shown to alter histamine-induced contraction in human airway smooth muscle,24 and although airway smooth muscle from several animal species contains P, receptors, it has been difficult to demonstrate them in autoradiographic studies of human airway smooth muscle.35 It might thus be that the partial agonist effect of salbutamol on 12 receptors, whilst sufficient to induce relaxation, does not provide the same protection against agonist-induced airway smooth muscle contractility as a full agonist such as adrenaline. It is possible that we underestimated the effects of adrenaline in vitro due to its metabolism, but we saw no diminution of its relaxant effect over the time course of our experiment and, in any case, this would serve only to magnify the disparity between its effects in vitro and in vivo.
We have considered several explanations for the lack of effect of adrenaline on histamine responsiveness in vivo despite its marked effect on airway smooth muscle in vitro. Adrenaline has several potentially beneficial actions. Its 02 agonist effect on airway smooth muscle would be expected to reduce histamine reactivity as it did in vitro and it would also reduce histamineinduced vasodilatation and capillary leakage through its a vasoconstrictor effects. The balance of its effects on the vasculature would be vasoconstrictor as it has much more potent a than 1, effects.
There are three mechanisms whereby vasoactive substances might alter bronchial responsiveness, apart from a direct effect on airway smooth muscle. Firstly, blood flow may affect airway wall thickness through vascular engorgement; secondly, alterations in microvascular leakage may alter airway responsiveness; and thirdly, vascular changes may alter the clearance ofbronchoactive substances from the airway. The net effect of these mechanisms will determine the effect of the vasoactive substance on airway reactivity.2 The lack of effect of adrenaline in vivo would suggest that a reduction in the vascular clearance ofhistamine due to the vasoconstrictor properties of adrenaline may have negated the other potentially beneficial effects on the vasculature and airway smooth muscle.
Further evidence to support this hypothesis is that reduction of tracheobronchial blood flow in dogs prolongs methacholine-induced bronchial obstruction,'0 and in man methacholine-induced bronchial obstruction is prevented by a potent vasodilator, prostacyclin."1 Similarly, allergen-induced bronchoconstriction in sensitised sheep is prolonged by the vasoconstrictor agent vasopressin, and reduced by the vasodilator nitroglycerin.9
The lack of effect of adrenaline on histamine responsiveness in our study contrasts with two studies showing that the a agonists methoxamine and noradrenaline protect against exercise and hyperventilation-induced airflow obstruction respectively.78 The apparent disparity in these results may be due to the mechanisms involved in the different types of challenge tests. In bronchoconstrictor challenges with exogenous histamine where smooth muscle contraction is the main mechanism of bronchoconstriction, the major effect of a vasoconstrictor may be to reduce the vascular clearance of inhaled histamine. In contrast, in challenges such as exercise and hyperventilation where thermally-induced vasodilatation may be contributing to the airflow narrowing,3 the effect of a vasoconstrictor may be to protect against this. The relation between bronchial blood flow and thermally-induced bronchoconstriction may be complex, however, as volume expansion can produce contrasting effects on hyperventilation-induced broncho-constriction depending on the timing of infusion. 36 An alternative explanation for the lack of effect of adrenaline on histamine reactivity in vivo is a pharmacokinetic one, namely that adrenaline was metabolised more quickly than salbutamol. While adrenaline does undergo more rapid metabolism than salbutamol, we feel that this is a less likely explanation for its lack of effect on histamine reactivity for several reasons. We performed histamine challenges only 10 minutes after the final dose of adrenaline and these were completed in 5-10 minutes. As bronchodilatation was still maximal at the start of the histamine challenge test, it would seem unlikely that the effect would have worn off in the ensuing 5-10 minutes. In conclusion, salbutamol and adrenaline have similar bronchodilator potencies when given by nebulisation in asthmatic subjects in vivo and when administered directly to airway smooth muscle in vitro. Despite a greater effect on histamine-induced contractions in vitro, adrenaline was less effective in protecting histamine-induced bronchoconstriction in vivo.
Our study suggests that the potential beneficial a adrenergic effects of adrenaline, such as reduced microvascular leakage and decrease in mucosal blood flow, do not protect against histamine-induced constriction in mild asthmatics when adrenaline is administered acutely by nebulisation. Furthermore, the vascular a effects of adrenaline may be antagonistic to the beneficial P2 effects, possibly by reducing vascular clearance of histamine. 
